Physician profile
Muhammad Kamran
NPI 1326019597
$5,630.07
in general payments reported to CMS, 2019-2025
36 companies · $950 in 2025
The $950 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,341 · 2020: $609 · 2021: $508 · 2022: $181 · 2023: $910 · 2024: $1,131 · 2025: $950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,508 · Travel and Lodging: $880 · Debt Forgiveness: $412 · Education: $192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,507.61 |
| Travel and Lodging | $879.62 |
| Debt Forgiveness | $412.00 |
| Education | $192.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Terumo Medical Corporation | $704.40 | 2019-2023 | Glidesheath Slender |
| Edwards Lifesciences Corporation | $627.74 | 2019-2025 | |
| Lantheus Medical Imaging, INC. | $428.57 | 2021-2025 | |
| Endologix LLC | $387.85 | 2024 | Torus Stent Graft System, Endocross Device |
| Novartis Pharmaceuticals Corporation | $375.87 | 2019-2025 | |
| Boston Scientific Corporation | $366.89 | 2020-2025 | General - Tachy, General - Therapies |
| Astrazeneca Pharmaceuticals LP | $324.51 | 2019-2025 | Farxiga |
| Amgen INC. | $310.21 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $266.37 | 2019-2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $199.09 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $182.35 | 2019 | |
| Abbott Laboratories | $177.54 | 2019-2024 | Gallant, Assurity |
| Biotronik INC. | $169.21 | 2019-2023 | Edora 8 Dr-T |
| E.R. Squibb & Sons, L.L.C. | $155.61 | 2019-2025 | Camzyos |
| Cardiva Medical, INC. | $127.68 | 2023-2025 | Cardiva Vascade 6/7f Vcs, Optowire, Cardiva Vascade 5f Vcs |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $104.26 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $86.81 | 2024 | |
| Sanofi-Aventis U.S. LLC | $76.97 | 2019 | |
| Novo Nordisk INC | $75.31 | 2025 | Wegovy |
| Ethicon US, LLC | $63.93 | 2021-2022 | |
| Elutia, INC. | $53.96 | 2019-2024 | Ecm Patch,Pouch |
| Amarin Pharma, INC. | $44.30 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $42.79 | 2021-2023 | Verquvo |
| Medtronic, INC. | $39.86 | 2021-2022 | |
| Siemens Medical Solutions USA, INC. | $35.57 | 2019-2024 | Diagnostic Ultrasound System, Acuson Origin Diagnostic Ultrasound System |
| Shockwave Medical, INC | $29.26 | 2025 | |
| Surmodics, INC. | $27.85 | 2023 | Sublime 014 Rx Pta Balloon Dilatation Catheter, Sublime Radial Access 018 Rx Pta Dilatation Catheter, Pounce Venous Thrombectomy System |
| Lexicon Pharmaceuticals, INC. | $25.07 | 2024 | |
| Vifor Pharma, INC. | $18.70 | 2021 | |
| Bard Peripheral Vascular, INC. | $17.78 | 2024 | Rotarexs 6 F X 135 Cm |
| Arbor Pharmaceuticals, INC. | $16.84 | 2020 | |
| Kiniksa Pharmaceuticals International, Plc | $14.62 | 2024 | Arcalyst |
| Portola Pharmaceuticals, LLC | $14.24 | 2019 | |
| Cardiovascular Systems INC. | $13.65 | 2019 | |
| Medtronic Vascular, INC. | $13.00 | 2020 | |
| Medtronic USA, INC. | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Kamran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.